comparemela.com

Latest Breaking News On - Poster discussion - Page 3 : comparemela.com

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023

– Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Hematologic, Genitourinary, Gastrointestinal, Gynecological and. | May 17, 2023

Foster cityUnited statesDomvanalimab domPembrolizumab pembroEtrumadenant etrumaAxicabtagene ciloleucelZimberelimab zimFrank neumannSanta monicaBrexucabtagene autoleucel brexuGilead sciencesDrug administrationGilead sciences incGilead companyAmerican society of clinical oncologyKite global head of clinical development

Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

/PRNewswire/ Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies.

United statesValerie malyvanh jansenYakun wangCorporate communications investor relationsElevation oncology incGroup limitedDrug administrationAmerican society of clinical oncologyPrnewswire elevation oncology incExchange commissionAmerican societyClinical oncologyElevation oncologyChief medical officerPoster discussionMolecularly targeted agents

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

/PRNewswire/ Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today.

United statesUnited kingdomSouth koreaRepublic of koreaMatthew deyoungSamuelj klempnerDouglase onsiLeap therapeutics incPrnewswire leap therapeutics incDrug administrationAmerican society of clinical oncologyHarvard medical schoolClinical oncologyAnnual meetingPresentation detailsHarvard medical

AISA Pharma Announces Upcoming Profervia® Data Presentations at AAN and EULAR

/PRNewswire/ Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company, today announced it will present data on its clinical drug candidate,.

United statesAndrew sternlichtAisa pharma incAmerican academy of neurologyPrnewswire aisa pharma incEuropean alliance of associationsPositive phaseSystemic sclerosisAmerican academyScientific platform sessionNoveln type specific calcium channel antagonistHas potent activityWhich may have implicationsCertain neuropathic painEuropean allianceNovel daily oral calcium channel blocker

ASCO 2022 | The First Dataset of Olverembatinib (HQP1351) in Patients with GIST Demonstrates Therapeutic Potential with a Clinical Benefit Rate of 83 3%

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),.

United statesHong kongWestern australiaInnovent biologicsAscentage pharmaBaibo qiuYifan zhaiPrnewswire ascentage pharmaMajor nationalAmerican society of clinical oncologyMd anderson cancer centerSun yat sen university cancer centerAmerican society of hematologyChina national medical products administrationNational major new drug discoveryDana farber cancer institute

vimarsana © 2020. All Rights Reserved.